Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 8/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8519316 | 1.00 | TSHR (0.48) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL8676416 | 1.00 | TSHR (0.48) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL20719804 | 0.81 | CYP2C9 (0.38) | MAOBHSD17B10GAAMAOAKMT2A | |
| SCHEMBL18366390 | 0.81 | MAOB (0.43) | MAOB | |
| SCHEMBL12220617 | 0.81 | ESR2 (0.50) | CYP19A1ADORA3HSD17B10MAPTPSMB5 | |
| SCHEMBL9405189 | 0.80 | TSHR (0.52) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL4453374 | 0.80 | CYP11B2 (0.44) | TSHRCYP19A1KDM4EKMT2A | |
| SCHEMBL4612628 | 0.77 | TSHR (0.48) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL29626019 | 0.77 | TSHR (0.48) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL13093911 | 0.76 | TSHR (0.48) | TSHRMAOBCYP19A1ARKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212184-B1 | SUBSTITUTED BENZOTETRAHYDROPYRANS AND THEIR USE | ABBVIE OVERSEAS SARL (LU) | 2020-04-01 | — | — | EP | disclosed |
| CN-107849023-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2018-03-27 | — | — | CN | disclosed |
| EP-3212184-A1 | SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE | Abbvie S.a.r.l. (LU) | 2017-09-06 | — | — | EP | disclosed |
| US-9567322-B2 | Substituted tetrahydropyrans and method of use | ABBVIE S.Á.R.L. (LU) | 2017-02-14 | — | — | US | disclosed |
| US-9567322-B2 | Substituted tetrahydropyrans and method of use | ABBVIE S.Á.R.L. (LU) | 2017-02-14 | — | — | US | disclosed |
| US-9567322-B2 | Substituted tetrahydropyrans and method of use | ABBVIE S.Á.R.L. (LU) | 2017-02-14 | — | — | US | disclosed |
| WO-2016069891-A1 | SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE | ABBVIE INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122331-A1 | SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2016-05-05 | — | — | US | disclosed |
| US-20160122331-A1 | SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2016-05-05 | — | — | US | disclosed |
| WO-2013010453-A1 | CHEMOKING RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2010064705-A1 | NOVEL 7-SUBSTITUTED DIHYDROPYRANOPYRIMIDINE DERIVATIVE HAVING H4 RECEPTOR ANTAGONISTIC ACTIVITY | 大日本住友製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009124882-A1 | NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124882-A1 | NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-10-15 | — | — | WO | disclosed |
| EP-0931139-A1 | IMMOBILIZED COFACTOR-DEPENDENT ENZYMES | McGILL UNIVERSITY (CA) | 1999-07-28 | — | — | EP | disclosed |
| US-5807926-A | OXIDO-REDUCTO SYNTHESIS | MCGILL UNIVERSITY (CA) | 1998-09-15 | — | — | US | disclosed |
| WO-1998016631-A1 | IMMOBILIZED COFACTOR-DEPENDENT ENZYMES | MCGILL UNIVERSITY (CA) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122331-A1 | SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE | CFTR, MRPL21, TACR1 | TSHR 285/4885MAOB 3077/4885CYP19A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.